Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration ...

Acute Care Events During Systemic Cancer Treatment: Moving From Risk Prediction to Clinical Decision Support Using a Two-Model Approach We conducted a retrospective, single-center study of patients ...

The researchers identified 3,263 events of disease recurrence or death in 12,834 patients; in the overall study population, the noninferiority of 3 months versus 6 months of treatment was not ...

Please provide your email address to receive an email when new articles are posted on . The addition of cediranib to chemotherapy did not improve survival in patients with previously untreated ...

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin ...

Importantly, all 4 of the patients whose disease was controlled to the point that they could proceed with metastasectomy are still alive. Only 1 patient had confirmed recurrence and required active ...

January 22 (Orlando, Florida) — In contrast to some previous studies that found no benefit with newer chemotherapy regimens in elderly colorectal cancer patients, a randomized phase 3 trial showed ...

PLYMOUTH MEETING, PA [August 7, 2023] — New research in the August 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network evaluates how an important analysis on local-regionally ...

SUZHOU, China, June 5, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, ...

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin ...